Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Abstract Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Masahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, Megumi Ikemori‐Kawada, Yukinori Minoshima, Yasuhiro Funahashi, Junji Matsui
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2018-06-01
coleção:	Cancer Medicine
Assuntos:	angiogenesis fibroblast growth factor hepatocellular carcinoma Lenvatinib vascular endothelial growth factor
Acesso em linha:	https://doi.org/10.1002/cam4.1517
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!